title: Chronic fluoxetine treatment attenuates post-septic affective changes in the mouse.
abstract: It has been previously demonstrated that the induction of sepsis in rodents results in persistent impairments in affective and cognitive domains. In this study we have examined the impact of chronic treatment with the antidepressant fluoxetine on affective behaviours and hippocampal neuroinflammation and stem cell proliferation in animals that have previously undergone sepsis induced by peripheral treatment with lipopolysaccharide. We find that fluoxetine significantly attenuates post-septic increases in behavioural despair and motivated exploration, whilst also reversing the effects of previous sepsis on activated microglia and stem cell proliferation. These results indicate that conventional antidepressants may be effective in the management of mood disorders in survivors of sepsis.
authors.affiliation: Maynooth University Department of Psychology, National University of Ireland, Maynooth, Ireland.
authors.forename: Sean T
authors.initials: ST
authors.lastname: Anderson
authors.affiliation: Maynooth University Department of Psychology, National University of Ireland, Maynooth, Ireland.
authors.forename: Sean
authors.initials: S
authors.lastname: Commins
authors.affiliation: Maynooth University Department of Biology, National University of Ireland, Maynooth, Ireland.
authors.forename: Paul
authors.initials: P
authors.lastname: Moynagh
authors.affiliation: Maynooth University Department of Psychology, National University of Ireland, Maynooth, Ireland. Electronic address: andrew.coogan@nuim.ie.
authors.forename: Andrew N
authors.initials: AN
authors.lastname: Coogan
mesh_terms: D000339:Affect / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D056547:CA1 Region, Hippocampal / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002135:Calcium-Binding Proteins / Q000378:metabolism; D018891:Dentate Gyrus / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D051766:Early Growth Response Protein 1 / Q000378:metabolism; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D005473:Fluoxetine / Q000494:pharmacology*; D007150:Immunohistochemistry; D008070:Lipopolysaccharides; D008297:Male; D008810:Mice, Inbred C57BL; D008840:Microfilament Proteins / Q000378:metabolism; D017628:Microglia / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D058953:Neural Stem Cells / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D055495:Neurogenesis / Q000187:drug effects / Q000502:physiology; D015213:Neuroimmunomodulation; D018805:Sepsis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000523:psychology
chemical_list: C491049:Aif1 protein, mouse; D000928:Antidepressive Agents; D002135:Calcium-Binding Proteins; D051766:Early Growth Response Protein 1; C486109:Egr1 protein, mouse; D008070:Lipopolysaccharides; D008840:Microfilament Proteins; D005473:Fluoxetine
keywords: BrdU; Depression; EGR1; Fluoxetine; Neuoinflammation; Sepsis